Agios Pharmaceuticals Inc. (AGIO)
AGIO trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$30.21
-1.98% on the day
Market cap
$1.8B
Small cap
Revenue · 2025
$54.0M
+48.0% on 2024
Net income · 2025
-$413.0M
-764.4% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | AGIO on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2013 |
| SEC CIK | 0001439222 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $54.0M |
| Net income | -$413.0M |
| Operating income | -$472.1M |
| Net margin | -764.4% |
| Operating margin | -873.9% |
| Revenue growth | +48.0% |
| Cash | $89.1M |
| Total assets | $1.3B |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 33.4× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2026-02-12 |
| Latest annual report | 10-K | 2026-02-12 |
| Latest quarterly / interim | 10-Q | 2026-07-30 |
| Latest current report | 8-K | 2026-07-30 |
| Latest proxy | DEFA14A | 2026-04-24 |
Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -2.6% |
| 1 month | -5.6% |
| 3 months | -20.0% |
| Year to date | +13.8% |
| 1 year | -24.3% |
| From 52-week high | -31.9% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ZYME | Zymeworks Inc. | $25.07 | -1.03% | $1.8B |
| PVLA | Palvella Therapeutics Inc. | $128.51 | -4.37% | $1.9B |
| MLYS | Mineralys Therapeutics Inc. | $21.00 | -5.53% | $1.9B |
| TRVI | Trevi Therapeutics Inc. | $12.29 | -4.95% | $1.8B |
| XERS | Xeris Biopharma Holdings Inc. | $10.20 | -2.49% | $1.9B |
| XNCR | Xencor Inc. | $23.52 | -6.07% | $1.7B |
| SRPT | Sarepta Therapeutics Inc. Common Stock (DE) | $16.51 | -5.33% | $1.7B |
| BRVE | Braveheart Bio Inc. | $19.33 | -5.06% | $1.7B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier